Quantcast

Latest Growth hormone treatment Stories

2011-07-26 12:28:00

Company expects to file New Drug Application QUÓ°BEC CITY, July 26, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The Company is currently proceeding with detailed analyses of the data and preparing for a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug...

2011-07-12 00:00:58

Growth Hormones Direct homeopathic HGH clinical trials currently underway are indicating weight loss potential available through homeopathic treatment with Growth Hormones Direct's Ultimate Homeopathic HGH Remedy. Phoenix, AZ (PRWEB) July 10, 2011 Growth Hormones Direct homeopathic HGH clinical trials are currently underway. While clinical trials are not yet completed, preliminary information indicates that Growth Hormones Direct's Ultimate Homeopathic HGH remedy offers significant weight...

2011-07-11 06:30:00

NES-ZIONA, Israel, July 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity...

2011-07-03 00:01:48

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, revealed the results of its annual patient satisfaction survey today. The survey, conducted by Gartner & Associates LLC in May 2011, reaffirms Diplomat's industry leading patient satisfaction rates. Key survey findings reflect: "¢ 99% of customer respondents were satisfied overall with Diplomat "¢ 98% indicated that Diplomat meets their expectations "¢ 90% indicated that...

2011-06-30 15:05:00

FLINT, Mich., June 30, 2011 /PRNewswire/ -- Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, revealed the results of its annual patient satisfaction survey today. The survey, conducted by Gartner & Associates LLC in May 2011, reaffirms Diplomat's industry leading patient satisfaction rates. Key survey findings reflect: 99% of customer respondents were satisfied overall with Diplomat 98% indicated that Diplomat meets their expectations 90%...

2011-06-29 17:22:00

PHILADELPHIA, June 29, 2011 /PRNewswire/ -- This evening, Novo Nordisk awarded sponsorships totaling $85,000 to four Philadelphia-based community organizations to educate local communities and raise awareness of diabetes to reduce the risk for long-term diabetes related complications. The sponsorships are part of the Novo Nordisk Community Care program, which aims to partner with local organizations to promote enduring, sustainable change at the local level for people living with...

2011-06-20 06:30:00

NES-ZIONA, Israel, June 20, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that its paediatric investigation plan for clinical development of its long-acting human growth hormone (hGH-CTP) has been accepted for review by the Paediatric Committee of the European Medicines Agency (EMA). Following promising efficacy and safety interim results in its ongoing Phase II trial of hGH-CTP in growth hormone-deficient adults, PROLOR is now actively pursuing development...

2011-06-13 06:30:00

NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP). The patent covers the composition of PROLOR's proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications. "This new patent covering...

2011-06-06 06:00:00

NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily. It was conducted using a state-of-the-art animal model specifically...

2011-06-06 05:00:00

NEW YORK and JERUSALEM, June 6, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate. Most important, the data illustrated that Octreolin reduced growth hormone (GH)...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related